capecitabine has been researched along with palbociclib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Robert, M; Turner, N | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Alba, E; Alvarez, I; Anton, A; Bermejo, B; Caballero, R; Calvo, L; Carrasco, E; Casas, MI; Chacón, JI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Garcia-Sáenz, JA; Gil-Gil, M; Guerrero-Zotano, A; Huang Bartlett, C; Huang, X; Kahan, Z; Koehler, M; Margeli, M; Martin, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Swift, C; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Agostinetto, E; Ignatiadis, M | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Alba, E; Alonso-Romero, JL; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, MI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodríguez, J; Gil-Gil, M; Huang, X; Kahan, Z; Margelí, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Sánchez-Rovira, P; Santaballa, A; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| Altundag, K | 1 |
| Antón, A; Belli, S; Bermejo, B; Bianco, R; Caballero, R; Ciruelos Gil, EM; Fernández-García, D; Fernandez-Serra, A; Formisano, L; Gil-Gil, M; Guerrero-Zotano, Á; Herranz, J; Liu, Y; López-Guerrero, JA; Margeli Vila, M; Martín, M; Muñoz-Mateu, M; Murillo, L; Nissenbaum, B; Pascual, J; Ruiz-Borrego, M; Turner, N; Zielinski, C | 1 |
5 trial(s) available for capecitabine and palbociclib
| Article | Year |
|---|---|
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; EGF Family of Proteins; Humans; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Fulvestrant; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin E; Cyclin-Dependent Kinase 4; Female; Humans; Oncogene Proteins; Polo-Like Kinase 1; Proto-Oncogene Proteins; Receptor, ErbB-2; RNA, Messenger | 2023 |
4 other study(ies) available for capecitabine and palbociclib
| Article | Year |
|---|---|
Endocrine-based therapy versus chemotherapy in advanced breast cancer.
Topics: Androstadienes; Breast Neoplasms; Capecitabine; Female; Gonadotropin-Releasing Hormone; Humans; Piperazines; Pyridines | 2019 |
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.
Topics: Aromatase Inhibitors; Breast Neoplasms; Capecitabine; EGF Family of Proteins; Humans; Piperazines; Pyridines | 2021 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen receptor
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2022 |